A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumours (MK-1775-001 AM7)

Official Title

A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumours

Summary:

This study will investigate MK1775 alone and in combination with one of the following three drugs: gemcitabine, cisplatin, and carboplatin in patients with advanced solid tumours. The purpose of the study is to test safety and tolerability of MK1775 alone and in combination, and to find the maximum tolerated dose (MTD) of MK1775 as monotherapy and in combination therapy.

Trial Description

Primary Outcome:

• Number of participants with dose limiting toxicities
• Change from baseline in biomarkers PHH3, CDC2, and pCDC2
• Plasma concentration of MK1775
• Urine concentration of MK-1775

• Number of participants with objective response

View this trial on ClinicalTrials.gov